Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Promising Results at 2 Years

Functional assessment of coronary artery lesions with fractional flow reserve (FFR) or instant wave-free ratio (IFR) have shown improvement of most symptoms and clinical outcomes of patients with stable CAD. However, these tools recommended by the current guidelines increase procedure complexity, risk and cost. 

Resultados alentadores a 2 años del índice de flujo cuantitativo 

This is why the angiographic quantitative flow ratio-guided coronary intervention (QFR) has been created and validated, with good and accurate reproducibility with FFR. With the FAVOR III China has shown at one year improved clinical results after PCI when using QFR vs using conventional angiography. 

The aim of this study was to determine whether the benefit of QFR persists at 2 years, particularly in patients where QFR changed revascularization strategy. 

Primary end point (PFP) was major adverse cardiovascular events (MACE) defined as all cause death, AMI, or ischemia driven revascularization. Secondary end point included MACE with no periprocedural AMI, procedure duration, amount of contrast, change of PCI strategy and cost effectiveness. 

3825 patients were randomized: 1913 to the QFR guided group and 1912 to the angiography guided group. Mean age was 62. The most frequent presentation was unstable angina (58%). Mean SYNTAX score was 9.5. The revascularization strategy was changed in 23% of patients in the QFR group and 6% in the conventional angiography group (p=0.0001) due to deferring treatment in those originally planned for PCI (19.6% vs. 5.2%, respectively, P<0.0001) and unplanned PCI in those not planned to receive it (4.4% vs 1.5% respectively, p<0.0001).

Read also: Patients with INOCA in the ISCHEMIA Trial.

Primary end point at 2 years was 8.5% in the QFR vs 12.5% in the conventional angiography group (HR 0.66, 95% CI 0.54-0.81; P<0.0001), at the expense of a lower rate of AMI (p=0.0002) and lower rate of clinical guided revascularization (p=0.02) in the QFR. MACE rate with no periprocedural AMI was also lower in the QFR (5.8% vs 8.8%, p=0.0004). 

Patients whose intervention strategy was modified saw higher relative reduction of MACE, with better outcomes in patients with lesions differed because of QFR outcomes. 

Conclusion

QFR guided lesion selection improved clinical outcomes at 2 years vs. Conventional angiography. The benefit was more pronounced in patients whose revascularization strategy was changed according to QFR. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention: Two-Year Outcomes of the FAVOR III China Trial.

Reference: Lei Song, MD, et al Journal of the American College of Cardiology (2022).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...